GSK961068

**GSK961068** is a bifunctional muscarinic antagonist-beta2 agonist (MABA) small molecule developed by Theravance for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). It combines long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) activities in a single molecule to provide dual bronchodilation, leveraging multivalent drug design to enhance efficacy and potentially reduce side effects compared to separate LAMA/LABA combinations. Partnered with GlaxoSmithKline (GSK), it was part of Theravance's respiratory pipeline but appears to have been discontinued as it is no longer listed in active development or GSK's product portfolio.